In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Miranda Novales, Guadalupe ^a   Leaños Miranda, Blanca E ^a   Vilchis Pérez, Mariano ^b   Solórzano Santos, Fortino ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFALOTIN; DICLOXACILLIN; IMIPENEM; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEPHALOTHIN; DICLOXACILLIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; IMIPENEM; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33750300138     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-25     Document Type: Article

References (26)

1. Christensen GD, Bisno AL, Parisi JT, McLaughlin B, Hester MG, Luther RW: Nosocomial septicemia due to multiply antibiotic resistant Staphylococcus epidermidis. Ann Intern Med 1982, 96:1-10.
2. Martin MA, Pfaller MA, Wenzel RP: Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med 1989, 110:9-16.
3. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ: Methicillin-resistant Staphylococcus aureus in US hospitals 1975-1991. Infect Control Hosp Epidemiol 1992, 13:582-586.
4. Suh K, Toye B, Jessamine P, Chan F, Ramotar K: Epidemiology of methicillin-resistant Staphylococcus aureus in three Canadian tertiary-care centers. Infect Control Hosp Epidemiol 1998, 19:395-400.
5. Aires de Sousa M, de Lencastre H, Santos Sanches I, Kikuchi K, Totsuka K, Tomasz A: Similarity of antibiotic resistant patterns and molecular typing properties of methicillin-resistant Staphylococcus aureus isolates widely spread in hospital in New York City and in a hospital in Tokyo, Japan. Micro Drug Resist 2000, 6:253-8.
6. Alpuche-Aranda C, Avila-Figueroa C, Espinoza-De los Monteros L, Gomez-Barreto D, Santos-Preciado JI: Patrón de sensibilidad antimicrobiana de Staphylococcus aureus en un Hospital Pediátrico: prevalencia de resistencia a meticilina. Bol Med Hosp Infant Mex 1989, 46:700-703.
7. Giraud MC, Calva JJ, Huazano F, Ponce de Leon S, Ruiz-Palacios G: Patrones de susceptibilidad a 19 antimicrobianos de gérmenes aislados de hemocultivos; en un hospital de referencia de la ciudad de México. Rev Invest Clin 1986, 38:7-14.
8. Solórzano-Santos F, Miranda-Novales MG, Díaz-Ponce H, Leaños-Miranda B, Fajardo-Gutiérrez A: Factores de riesgo para sepsis en pacientes pediátricos con infección por Staphylococcus coagulasa negativa. Bol Med Hosp Infant Mex 1994, 51:384-388.
9. Urdez-Hernandez E, Sifuentes-Osornio J, Calva JJ, Vilialobos-Zapata Y: Epidemiological and biological characteristics of methicillin-resistant staphylococcall infections in a Mexican Hospital. Arch Med Res 1999, 30:325-31.
10. Santos Sanches I, Mato R, de Lencastre H, Tomasz A, CEM/NET Collaborators and the International Collaborators.: Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative Staphylococci collected in the International Multicenter Study Resist in 1997 and 1998. Microb Drug Res 2000, 6:199-211.
11. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC: Accesory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. C I D 2004, 38:1700-05.
12. CLSI (Clinical and Laboratory Standards Institute): Performance Standards for Antimicrobial Susceptibility testing. Fifteenth Informational Supplement. CLSI document M100-515. Pennsylvania USA 2005:19087-1898.
13. Tenover FC, Jones RN, Swenson JM, Zimmer B, McAllister S, Jorgensen JH: Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study. J Clin Microb 1999, 37:4051-58.
14. Kohner P, Uhl J, Kolbert C, Persing D, Cockerill F 3rd: Comparison of susceptibility testing methods with mec A gene analysis for determining oxacillin (methicillin) resistance in clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus spp. J Clin Microbial 1999, 37:2952-61.
15. Velázquez-Meza ME, Aires de Sousa M, Echaniz-Aviles G, Solorzano-Santos F, Miranda-Novales G, Silva-Sanchez J, de Lencastre H: Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City during a 7-year period (1997-2003): Clonal evolution and impact of infection control. J Clin Microbiol 2004, 42:3877-80.
16. Norden CW, Wentzel H, Keleti E: Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis 1979, 140:629-33.
17. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F: In vitro synergistic effects of double and triple combinations of blactams, vancomycin and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000, 44:3055-60.
18. Eliopolus GM, Moellering RC Jr. Antimicrobial combinations. In Antibiotics in Laboratory medicine. 3rd edition. Williams and Wilkins, Co. Baltimore, MD USA; 2000:432-49.
19. Dawis MA, Isenberg HD, France KA, Jenkins SG: In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 2003, 51:1203-11.
20. Climo MW, Patron RL, Archer GL: Combinations of vancomycin and b-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999, 36:1747-53.
21. Raymond J, Vedel G, Bergeret G: In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. J Antimicrob Chemother 1996, 38:1067-71.
22. Le T, Bayer AS: Combination antibiotic therapy for infective endocarditis. C I D 2003, 36:615-21.
23. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW: Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 2003, 47:3768-73.
24. Snydman DR, McDermott LA, Jacobus NV: Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother 2005, 17:614-21.
25. Lozniewski A, Lion C, Mory F, Weber M: In vitro synergy between cefepime and vancomycin against methicillin-susceptible and-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 2001, 47:83-6.
26. Raymond J, Vedel G, Bergeret M: In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. J Antimicrob Chemother 1996, 38:1067-71.